TAM is a nonsteroidal anti-estrogen that has been commonly used for the prevention and treatment of estrogen receptor-positive breast cancer. TAM is extensively metabolized into several primary active metabolites including 4-OH-TAM and endoxifen. Glucuronidation is the major phase II metabolic pathway important in their excretion. While high anti-estrogenic activity has been reported for both 4-OH-TAM and endoxifen, studies examining the effect of glucuronide conjugation of these metabolites have not previously been performed. In the present study, the antiestrogenic activities of glucuronidated TAM metabolites were determined by examining their effect on the induction of the estrogen-responsive PGR gene. E 2 -mediated PGR gene expression in MCF-7 cells was determined by real-time RT-PCR for each TAM metabolite isomer. E 2 (1x10 -10 M) induction of PGR mRNA was 6-fold after 12 h incubation; only unconjugated TAM metabolites inhibited this effect. A virtually identical dose-dependent inhibition of E 2 -induced PGR gene expression was found for both the trans and cis isomers of 4-OH-TAM and endoxifen, with maximal inhibition attained at 1 x10 -6 M of TAM metabolite. The glucuronide conjugates of all 4-OH-TAM and endoxifen isomers exhibited no effect on E 2 -mediated induction of PGR expression at all concentrations of TAM metabolite examined in this study. These data indicate that isomers of both 4-OH-TAM and endoxifen exhibit roughly equipotent anti-estrogenic effects on E 2 -induced gene expression and that glucuronide conjugates of the same metabolites effectively negate this activity. This may have important implications in terms of both whole-body and target-tissue-specific glucuronidation pathways and individual response to TAM therapy and cancer prevention.
Introduction
TAM, (1-[4-(2-dimethylaminoethoxy)-phenyl]-1,2-diphenylbut-1-(Z)-ene) is the most commonly prescribed chemotherapeutic and chemopreventive anti-estrogen for the management of estrogen receptor-positive breast cancer (Fisher et al., 1998; Osborne, 1998; Cuzick et al., 2003; Howell et al., 2003) . Adjuvant TAM treatment significantly increases recurrence-free survival and overall survival in estrogen receptorpositive breast cancer patients (Osborne, 1998; Howell et al., 2003) . As a selective estrogen receptor modulator, TAM competes with estrogen for binding to the ER and therefore inhibits tumor growth by interfering with the survival and proliferative signals regulated by estrogen. Although TAM is generally well-tolerated, there is significant inter-individual variability in the clinical efficacy of TAM as well as in the toxicities of TAM. For instance, TAM resistance and relapse have been developed in about 30% of the estrogen receptor-positive breast cancer patients (1998) . In addition to its antiestrogenic-related side effects such as hot flashes and vaginal bleeding (Osborne, 1998) , TAM may also increase the risk for endometrial cancer (van Leeuwen et al., 1994; Rutqvist et al., 1995) . TAM also has partial estrogenic effects that may be linked to reduced risk of ischemic heart disease and osteoporosis (McDonald and Stewart, 1991; Rutqvist and Mattsson, 1993) . The mechanisms underlying variability in response to TAM and TAM-related toxicities are not very clear but may be related to the altered patterns of TAM metabolism.
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After oral administration, TAM is extensively metabolized by phase I and phase II enzymes into several primary and secondary metabolites (Figure 1 ). Two of its hydroxylated metabolites, trans-4-OH-TAM and 4-hydroxy-N-desmethyl-TAM (also known as endoxifen) exhibit high affinity for ER, exhibiting up to 100 times more antiestrogenic activity in vitro than TAM itself as well as other TAM metabolites (Crewe et al., 1997; Dehal and Kupfer, 1997; Coller et al., 2002; Crewe et al., 2002; Coller, 2003; Hu et al., 2003; Desta et al., 2004) . Since both 4-OH-TAM and endoxifen are abundant in the serum of women treated with TAM, with endoxifen present at 6-12-fold the levels of 4-OH-TAM (Stearns et al., 2003; Desta et al., 2004; Jin et al., 2005) , these two TAM metabolites may be the major contributors to TAM's anti-estrogenic properties. While cis-4-OH-TAM is primarily thought to be an estrogen agonist with a weak estrogenic effect (Furr and Jordan, 1984) , studies on individual diastereomeric forms of endoxifen have not been previously examined.
A major mode of phase II metabolism of TAM is by glucuronidation catalyzed by the UGT family of enzymes. TAM is excreted predominantly through the bile, a process facilitated by TAM conjugation to glucuronic acid catalyzed by UGTs (Lien et al., 1989) .
TAM-glucuronide conjugates have been identified in the urine, serum and bile of TAMtreated breast cancer patients (Lien et al., 1988; Lien et al., 1989; Poon et al., 1993) , and it has been suggested that glucuronidation within target tissues like adipose tissue of the breast may also be important in terms of TAM metabolism and overall TAM activity (Nowell et al., 2005 demonstrated that methylation of the free phenolic group of 4-OH-TAM (producing a methyl-ether) significantly decreases the affinity of 4-OH-TAM for the estrogen receptor (Allen et al., 1980) . The goal of the present study is to test the hypothesis that glucuronidation of hydroxylated TAM metabolites reduces the anti-estrogenic activity of 4-OH-TAM and endoxifen. In this study, the relative anti-estrogenic activities of glucuronidated conjugates of the trans and cis isomers of 4-OH-TAM and endoxifen as compared to their unconjugated counterparts were examined. In addition, this is the first study examining the relative anti-estrogenic activities of individual endoxifen isomers.
This article has not been copyedited and formatted. The final version may differ from this version. OH-TAM (70%:30% ratio) and trans-:cis-endoxifen stocks by HPLC as previously described (Sun et al., Submitted) . Briefly, isocratic elution was performed using a Luna TAM, trans-endoxifen and cis-endoxifen were prepared by incubating with pig liver microsomes, which were prepared essentially as previously described for human liver microsomes (Fang and Lazarus, 2004; Wiener et al., 2004b For -N-Gluc products, homogenates (50 µg) from human UGT1A4-overexpressing HK293 cells (Wiener et al., 2004a) were used in glucuronidation reactions (performed as described above in a total reaction volume of 100 µL) since pig liver cannot form N-glucuronidated products of TAM or its metabolites (unpublished results).
For trans-and cis-4-OH-TAM-N-Gluc, HPLC separation started at 60% buffer A and 40% acetonitrile. As described previously, no N-Gluc products of trans-or cis-endoxifen were detected in glucuronidation reaction using human liver microsomes or homogenates from UGT1A4-over-expressing cell lines (Sun et al., Submitted) . TAM-NGluc was synthesized using UGT1A4-over-expressing cell homogenates as previously described (Sun et al., 2006) and separation started with 50% buffer A:50% acetonitrile 
trans-and cis-4-OH-TAM-O-Gluc and trans-and cis-endoxifen-O-Gluc was initiated with
70% buffer A (0.5 M NH 4 AOc, pH = 5.0) and 30% acetonitrile for 3.5 min, followed by a subsequent linear increasing gradient to 75% acetonitrile (25% buffer A) over 0.5 min, and then maintained at 75% acetonitrile for 2 min. The flow rate was 0.3 mL/min. 
PGR expression analysis.

Results
Interconversions of trans-and cis-isomers of 4-OH-TAM or endoxifen.
Previous studies have suggested that there is spontaneous interconversion between the trans and cis isomers of 4-OH-TAM in culture media (Katzenellenbogen et al., 1984) . To examine the isomer interconversion in our experimental model, the percent interconversion between isomers of 4-OH-TAM and endoxifen was measured in treatment media under various pH conditions for up to 24 h. As shown in Figure 2 (panel A), approximately 2% of trans-4-OH-TAM was converted to cis-4-OH-TAM after 12 h of incubation in standard cell culture conditions at pH > 7.5. Less than 5%
interconversion was observed after 24 h incubation at these pHs. Similarly, < 2% of cis- Figure   2 , panel B). This observation is important since the biological effect of 4-OH-TAM has been suggested to be dependent upon its isomeric state -the trans-isomer is a potent anti-estrogen whereas the cis-isomer has been suggested to be a weak estrogen agonist (Furr and Jordan, 1984; Stearns et al., 2003; Desta et al., 2004; Jin et al., 2005) . The percent interconversion of the trans and cis isomers of endoxifen were 
4-OH-TAM was converted to trans-4-OH-TAM after 24 h incubation at pH > 7.5 (
Discussion
While the major mode of metabolism of TAM is by glucuronidaion through the bile (Lien et al., 1989) , TAM glucuronides have been detected in the serum of TAMtreated patients (Lien et al., 1988; Lien et al., 1989) . While glucuronidation pathways are largely hepatic, local glucuronidation activity within target tissues including the breast may impact the local pharmacological effect of TAM (Nowell et al., 2005) . Therefore, it is clearly important to understand the potential impact of glucuronidation as a potential deactivation step on the pharmacological effects of TAM.
As described in previous studies, 4-OH-TAM and endoxifen exhibit up to 100 times the level of anti-estrogenic activity as compared to TAM itself as measured by inhibition of E 2 -induced increases in cell growth, stimulation of plasminogen activator activity or induction of PGR gene expression (Jordan et al., 1977; Furr and Jordan, 1984; Katzenellenbogen et al., 1984; Murphy et al., 1990; Stearns et al., 2003; Johnson et al., 2004; Lim et al., 2004; Lim et al., 2005) . Previous studies also showed that the anti-estrogenic activities of 4-OH-TAM and endoxifen were approximately equivalent (Jordan et al., 1977; Stearns et al., 2003; Johnson et al., 2004; Lim et al., 2004; Lim et al., 2005) . In this report, no effect on E 2 induction of PGR expression was observed in cells treated with glucuronide conjugates of active TAM metabolites across the same range of TAM metabolite doses that inhibit E 2 induction in vitro and that mimic the TAM concentrations (20 mg/day) administered to women in vivo (Lee et al., 2003; Stearns et al., 2003) . This pattern was observed for trans and cis isomers of both endoxifen and 4-This article has not been copyedited and formatted. The final version may differ from this version. OH-TAM glucuronides. These data strongly suggest that the glucuronide conjugates of both 4-OH-TAM and endoxifen render these metabolites inactive at relevant doses. This is particularly important with respect to residual circulating liver-initiated TAM glucuronides that were not excreted into bile as well as adipose-dependent glucuronidation effects, since alterations in glucuronidation capacity could therefore significantly impact the local pharmacology within target tissues.
Previous studies examining the anti-estrogenic properties of TAM metabolite isomers have been hindered by the fact that interconversion between the cis and trans isomers of TAM and TAM metabolites shown to occur in previous experimental systems (Jordan et al., 1981; Lieberman et al., 1983; Katzenellenbogen et al., 1984) . The present study is the first to examine the anti-estrogenic properties of relatively pure isomers of both 4-OH-TAM and endoxifen. This was made possible by the fact that
results from the present study demonstrated that the interconversion properties of TAM metabolite isomers are highly pH-dependent, with decreasing interconversion occurring at higher pHs (7.8-8.4). While significant interconversion (up to 14%) was observed between trans and cis isomers at lower pH's, there was < 3% conversion between trans and cis isomers for both 4-OH-TAM and endoxifen after 12 h incubation in the cell culture media used in this study. This level of interconversion remained relatively constant over the time course examined with or without the presence of E 2 and/or TAM metabolite. This contrasts with the up to 18% isomer interconversion observed over a similar incubation time in previous study (Katzenellenbogen et al., 1984) . Therefore, unlike previous in vitro cell culture systems where the pH may not have been optimal to This article has not been copyedited and formatted. The final version may differ from this version. prevent interconversion between isomers, the anti-estrogenic properties of relatively pure isomers of TAM metabolites were examined in this study.
Previous studies have shown that the cis and trans isomers of 4-OH-TAM exhibit similar patterns of anti-estrogenic activities. Interpretation of results from previous studies was made difficult due to possible interconversion between isomers. It was originally suggested that since cis-TAM is estrogenic, the anti-estrogenic properties of cis-4-OH-TAM in a rat uterine weight test model may be due to interconversion to its trans-form (Jordan et al., 1981) . Later study using a prolactin synthesis model demonstrated a stronger anti-estrogenic effect for trans-4-OH-TAM as compared to cis-4-OH-TAM and that neither isomer exhibited estrogenic properties, but these data were also confounded by the possibility of interconversion between isomers (Lieberman et al., 1983) . Similarly, suppression of MCF-7 cell growth and E 2 -induced stimulation of plasminogen activator activity by the cis isomer of 4-OH-TAM was suggested to be due to isomer interconversion (Katzenellenbogen et al., 1984) . This was confirmed in studies of fixed-ring trans-and cis-isomers of TAM and 4-OH-TAM, which prevented isomer interconversion (Murphy et al., 1990) . The inhibition of E 2 -mediated induction of PGR gene expression was roughly equivalent for the trans-versus cis-isomers of 4-OH-TAM in previous studies (Lim et al., 2005) , a pattern similar to that observed in the present study for both 4-OH-TAM as well as endoxifen. These data suggest that the trans and cis isomers of these active TAM metabolites exhibit similar properties in terms of inhibition of E 2 -mediated induction of PGR gene expression and other E 2 -mediated cellular properties. This is the first study to examine the anti-estrogenic effects of individual isomers of endoxifen. Results from the present study demonstrate that both the trans and cis isomers of endoxifen exhibit anti-estrogenic activity. Similar levels of reduction in E 2 -induced PGR gene expression was observed for the two endoxifen isomers at all TAM metabolite doses examined in this study. Interestingly, the same level of inhibition of E 2 -induced expression of PGR was observed for endoxifen isomers as for isomers of 4-OH-TAM. This is similar to the anti-estrogenic properties observed for the two TAM metabolites in previous studies (Stearns et al., 2003; Johnson et al., 2004; Lim et al., 2005) . Also similar to that observed in previous studies (Katzenellenbogen et al., 1984) is the fact that TAM exhibited no effect on E 2 -induced PGR expression in MCF-7 cells at all TAM concentrations tested. This further supports the fact that it is the TAM metabolites, 4-OH-TAM and endoxifen, and not TAM itself, which are the active antiestrogens in women treated with TAM.
Consistent with the anti-estrogenic properties of the trans isomer of 4-OH-TAM and endoxifen, PGR gene expression was slightly inhibited when MCF-7 cells were incubated in the absence of E 2 . In contrast, there was no effect on the PGR gene expression by the corresponding cis isomers. This is consistent with a decreased antiestrogenic potential for the cis isomers of these TAM metabolites.
The results from this study suggest that glucuronidation is an important detoxifying and deactivating metabolic pathway for TAM. Since TAM is an important M after 24 h incubation (i.e., the maximum inhibition of E 2 -mediated induction of PGR expression observed in these studies). The vehicle was 0.1% DMSO. The E 2 positive control, the media along and vehicle negative control are shown on all three panels. E 2 , cells incubated with 1×10 -10 M E 2 ; vehicle, cells incubated with 0.1%
DMSO; trans-4-OH, cells incubated with trans-4-OH-TAM; cis-4-OH, cells incubated with cis-4-OH-TAM, trans-4-OH-O, cells incubated with trans-4-OH-TAM-O-glucuronide; cis-4-OH-O, cells incubated with cis-4-OH-TAM-O-glucuronide; trans-4-OH-N, cells
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